FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting